Why Is Foghorn Therapeutics ( $FHTX) Stock Down -47.34% Today? (Find out why any stock moved today on Tickeron.) Shares plunged roughly 47% after Foghorn Therapeutics (FHTX) and Eli Lilly (LLY) mutually agreed to discontinue their lead oncology program. The companies halted development of FHD-909, a SMARCA2 inhibitor, after Phase 1 data showed favorable safety but insufficient efficacy to justify advancement. A second collaborative program — the selective SMARCA2 degrader — was also dropped, effectively ending the partnership. $ARVN $DNLI $EDIT $KURA
published
Why Is Foghorn Therapeutics ( $FHTX) Stock Down -47.34% Today? (Find out why any stock moved today on Tickeron.) Shares plunged roughly 47% after Foghorn Therapeutics (FHTX) and Eli Lilly (LLY) mutually agreed to discontinue their lead oncology program. The co
$FHTX$ARVN$DNLI$EDIT$KURA
Latest documented BWB result
$APP market result
Sold the $280 10/9 Calls on $APP for $7.80
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.